Here are the key results: STEP 1 Trial (Standard 2.4 mg Dose) Participants lost an average of approximately 14.9% of their body weight over 68 weeks One-third of participants lost 20% or more of their body weight For a patient starting at 100 kg, this equates to approximately 15 kg (about 2 stone 5 lbs) of weight loss STEP 8 Trial (Higher 7.2 mg Dose) The newer, higher dose achieved approximately 20.7% body weight loss Nearly half of participants lost 20% or more of their body weight This dose narrows the gap between Wegovy and Mounjaro in terms of average weight loss What This Means in Practical Terms For patients in Northern Ireland starting Wegovy at a typical body weight, the results translate to meaningful, life-changing weight loss: Starting weight 90 kg (14 stone 2 lbs): Expected loss of approximately 13.4 kg (2 stone 2 lbs) Starting weight 105 kg (16 stone 7 lbs): Expected loss of approximately 15.6 kg (2 stone 6 lbs) Starting weight 120 kg (18 stone 13 lbs): Expected loss of approximately 17.9 kg (2 stone 12 lbs) Beyond the weight loss itself, clinical trial participants consistently reported improvements in blood pressure, blood sugar control, cholesterol levels, waist circumference, and quality of life
According to the trial, semaglutide met the study's primary endpoints and was superior to placebo in significantly reducing body weight and knee osteoarthritis-related pain, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score
This structural alteration is believed to facilitate more sustained engagement with intracellular signaling cascades
Blood glucose levels must be maintained at all times to avoid hypoglycemia and to supply the brain with its preferential fuel
This can lead to sarcopenic obesity, a condition where an individual reaches a healthy weight on the scales but retains a disproportionately high body fat percentage
[Abstract] CNS Neurosci Ther
-1775582746855.png&w=3840&q=75)
